Cartesian Therapeutics Announces Phase 2 Retreatment Data for Descartes-08

What Happened
Cartesian Therapeutics, Inc. (RNAC) announced additional retreatment data from its Phase 2 trial of Descartes-08 in patients with myasthenia gravis in an 8-K and press release dated September 29, 2026. The update describes outcomes from five participants who experienced symptom recurrence (MG-ADL ≥6) after 12 months following their initial Descartes-08 treatment and were retreated a median of 16.6 months after that initial course.

Key Details

• Sample: data reflect observations from 5 retreated participants in the Phase 2 MG study.
• Timing: median time to retreatment was 16.6 months after completion of the initial treatment course.
• Efficacy: retreated patients showed an average MG-ADL reduction of 6.6 (±4.2) points and an average Myasthenia Gravis Composite (MGC) reduction of 15 (±6.2) points from baseline at Month 12 post-retreatment. All 5 patients met clinically meaningful improvement thresholds (MGC ≥3 and MG-ADL ≥2); 4 maintained the MG-ADL benefit through Month 12.
• Safety: retreatment was generally well tolerated through Month 12; adverse events were transient and mild, no serious adverse events reported, and no cases of cytokine release syndrome, ICANS, cytopenias, or hypogammaglobulinemia were observed.

Why It Matters
For investors, these results highlight that retreatment with Descartes-08 produced measurable clinical benefit and maintained a favorable safety profile in this small group of Phase 2 patients, suggesting a potential retreatment strategy if symptoms recur. However, the observations are from only five participants, so larger studies will be required to confirm durability, safety, and broader applicability. The company’s disclosure may be relevant to expectations about clinical development progress and future trial design.